Study of an Investigational Medication for Patients with Previously Untreated Head and Neck Squamous Cell Carcinoma
Study identifier:D7919C00706
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase II Randomized, Double-blind, Placebo-controlled, Multicenter Comparative Study of ZD1839 250 mg or 500 mg (Iressa™) given either Continuously or Concomitantly with Cisplatin plus Radiotherapy for the Treatment of Patients with Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell Carcinoma
Medical condition
Carcinoma, Squamous Cell
Phase
Phase 2
Healthy volunteers
Yes
Study drug
ZD1839
Sex
All
Actual Enrollment
-
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Nov 2004
Primary Completion Date: 01 Jun 2008
Study Completion Date: 01 Jun 2008
Study design
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: None
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
